MedicinesFAQ

Blinatumomab Uses, Dosage, Side Effects and more

Blinatumomab is a BiTE-class (bi-specific T-cell engagers) constructed monoclonal antibody indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto™. A full treatment regimen consisting of two cycles of four weeks each, is priced at $178 000 USD. Blinatumomab was approved in December 2014 under the FDA’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease based on clinical data showing the drug has an effect on a surrogate endpoint reasonably likely to predict clinical benefit to patients.

Attribute Details
Trade Name Blinatumomab
Availability Prescription only
Generic Blinatumomab
Blinatumomab Other Names Blinatumomab
Related Drugs methotrexate, doxorubicin, imatinib, Gleevec, mercaptopurine, Sprycel
Type
Formula C2367H3577N649O772S19
Weight 54100.0 Da
Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated: January 7, 2025 at 1:49 am
   

Uses

Blinatumomab is an antineoplastic antibody used to treat Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

Blinatumomab is also used to associated treatment for these conditions: Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory, Relapsed B cell precursor Acute lymphoblastic leukemia

How Blinatumomab works

Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T cells. It activates endogenous T cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B cells. Blinatumomab mediates the formation of a synapse between the T cell and the tumor cell, upregulation of cell adhesion molecules, production of cytolytic proteins, release of inflammatory cytokines, and proliferation of T cells, which result in redirected lysis of CD19+ cells.

Toxicity

Food Interaction

No interactions found.

Blinatumomab Hypertension interaction

[Major] The use of monoclonal antibodies administered via IV infusion may cause serious infusion reactions, including bronchospasm, hypoxia, dyspnea, fluctuations in blood pressure, laryngeal edema and pulmonary edema.

Caution should be taken in patients with a history of cardiopulmonary disease as they may require additional post-infusion medications to manage respiratory complications.

It is recommended to administer required intravenous hydration and premedication with antihistamines, analgesics, and antipyretics before administration.

Monitor closely for signs and symptoms of infusion reactions during and for at least 4 hours following completion of each infusion in a setting where cardiopulmonary resuscitation medication and equipment are available.

Immediately interrupt or permanently discontinue treatment and institute supportive management for severe or prolonged infusion reactions as appropriate.

Drug Interaction

Unknown: paclitaxel protein-bound, charcoal, nifedipine, amphetamine / dextroamphetamine, multivitamin with minerals, zolpidem, copper gluconate, arginine, levocarnitine, cysteine, lithium, acetaminophen, bioflavonoids, valproic acid, thiamine, cyanocobalamin, pyridoxine, cholecalciferol, phytonadione, menaquinone

Disease Interaction

Major: infections, vaccination, infusion reactions, tumor lysis syndromeModerate: liver dysfunction, neurologic disorders, neutropenia, pancreatitisMinor: renal impairment

Volume of Distribution

4.52 L, standard deviation 2.89.

Half Life

2.11 hours, standard deviation 1.42.

Clearance

2.92 L/hour, standard deviation 2.83.

Innovators Monograph

*** Taking medicines without doctor's advice can cause long-term problems.